Skip to contentN
Neogenomics Inc
N
NEONeogenomics Inc Q3 2020 · 10-Q
Revenue$125.44M$125.44M+19.8% vs Q3 2019 Net Income$2.56M$2.56M+19.3% vs Q3 2019 EPS Diluted$0.04$0.04+100.0% vs Q3 2019 Gross Profit$54,065,000+6.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Neogenomics Inc · CIK 1077183 · Engraved from SEC EDGAR
Operating Cash Flowderived$526,000−97.2% Free Cash Flowderived-$7,331,000N/M Margins · derivedGross margin43.1%−5.5 pt vs Q3 2019
Operating margin3.7%+0.2 pt vs Q3 2019
Net margin2.0%−0.0 pt vs Q3 2019
ended Sep 30, 2020 · filed Oct 29, 2020 · 29 d after period end